美国个性化医疗公司Cancer Genetics正计划IPO,通过公开发行400万股,募集4800万美元。募集的资金部分将用于其诊断试剂的进一步研发、向监管部门申请批准和市场营销。
Cancer Genetics Inc. expects its initial public offering of 4 million common shares to price between $11 and $13 each.
The developer of genetic tests to detect cancer filed plans in December for an estimated IPO of up to $50 million to fund research and development and to repay debt.
Cancer Genetics develops genetic tests for difficult-to-diagnose cancers such as blood cancers, urinary and genital cancers, and those related to the human papillomavirus.
The company's 2011 loss widened to $19.9 million from $8.41 million a year earlier amid sharply higher operating expenses and fair-value impacts, while revenue grew 20% to $3.02 million, according to its regulatory filing.
The company intends to apply to list its shares on the Nasdaq Global Market under the symbol CGIX.